Drug intelligence / Profile preview

SAR441566 + methotrexate

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

SAR441566 + methotrexate is an investigational combination therapy studied in adults with moderate-to-severe rheumatoid arthritis who are not adequately controlled on methotrexate and are naive to biologic/targeted synthetic DMARDs. SAR441566 is a novel oral small molecule being developed as an add-on to background methotrexate therapy to improve disease outcomes in rheumatoid arthritis. Methotrexate is an established disease-modifying antirheumatic drug (DMARD) with anti-inflammatory and immunosuppressive effects, widely used as a first-line agent in rheumatoid arthritis[1][2][4][6].

Other names: MTXMethotrexate

Targets

NADH:ubiquinone oxidoreductase subunit familyDHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on SAR441566 + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR441566 + methotrexate.

Explore the full profile